Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders

Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders

  • CN 1,794,981 A
  • Filed: 05/27/2004
  • Published: 06/28/2006
  • Est. Priority Date: 05/27/2003
  • Status: Active Application
First Claim
Patent Images

1. , is selected from the dysthymic disorder'"'"'s of depression, dysthymia, seasonal affective disorder, bipolar disorder and postpartum depression method among a kind of patient of treatment, this method comprises that the patient to needs treatments gives a kind of combination, and this combination comprises the treatment effective dose:

  • (i) chemical compound of first quantity, this chemical compound has functional antagonist properties to N-methyl-D-aspartate (NMDA) receptor complex;

    WithThe (ii) selectivity 5-hydroxy tryptamine reuptake inhibitor (SSRI) of second quantity, it is citalopram or escitalopram, wherein the described obstacle of the combined therapy of first and second quantity is effective.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×